The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice

The SGLT2 inhibitor, Empagliflozin, is shown to exert cardioprotective effects by increasing mitochondrial ATP in a mouse model of diabetes.

Bibliographic Details
Main Authors:	Jungmi Choi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, Aki Oomachi, Yutaro Kotobuki, Yoichi Nishiya, Michael Paul Pieper, Hiromi Imamura, Motoko Yanagita, Masamichi Yamamoto
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-03-01
Series:	Communications Biology
Online Access:	https://doi.org/10.1038/s42003-023-04663-y

Internet